midazolam

✓ Approved

Rafa Laboratories Ltd · GABRA1 · Small Molecule

What is midazolam?

midazolam is a small molecule developed by Rafa Laboratories Ltd. It is approved for therapeutic indications via injectable (others) or intramuscular (im) injection.

Drug Profile

Company	Rafa Laboratories Ltd
Drug Class	Small Molecule
Molecular Target	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5
Route	Injectable (Others), Intramuscular (IM) Injection
Status	Approved

Sources: ClinicalTrials.gov, Rafa Laboratories Ltd

Mechanism of Action

Molecular Targets

midazolam acts on 5 molecular targets:

GABRA1	gamma-aminobutyric acid type A receptor alpha1 subunit (DEE19, ECA4)
GABRA2	gamma-aminobutyric acid type A receptor alpha2 subunit (DEE78, EIEE78)
GABRA3	gamma-aminobutyric acid type A receptor alpha3 subunit (EPILX2)
GABRA4	gamma-aminobutyric acid type A receptor alpha4 subunit ()
GABRA5	gamma-aminobutyric acid type A receptor alpha5 subunit (EIEE79, DEE79)

Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

midazolam is developed for 1 unique indication across 1 therapeutic area.

Therapeutic Area	Condition	Phase
Nervous system disorders	Status epilepticus	✓ Approved